Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of Permixon®

Journal of Steroid Biochemistry and Molecular Biology

Volumn 82, Issue 2-3, 2002, Pages 233-239

  Raynaud, Jean Pierre ^a   Cousse, Henri ^b   Martin, Pierre Marie ^c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c INSERM   (France)

Author keywords

5 Reductase; Fatty acids; Permixon ; Prostate; Serenoa repens extract

Indexed keywords

ANDROSTANOLONE; BEHENYL ALCOHOL; FATTY ACID; FATTY ACID ESTER; ISOENZYME; LAURIC ACID; LAURIC ACID ETHYL ESTER; LINOLEIC ACID; MYRISTIC ACID; OLEIC ACID; OLEIC ACID ETHYL ESTER; PALMITIC ACID; SABAL EXTRACT; SITOSTEROL; STEARIC ACID; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TOCOPHEROL; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL CELL; ARTICLE; AUTOGRAPHA CALIFORNICA; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSECT CELL; LEPIDOPTERA; MEDICINAL PLANT; MOLECULAR CLONING; NONHUMAN; PH; REPRODUCIBILITY; SABAL;

ANDROGEN ANTAGONISTS; ANIMALS; ANTILIPEMIC AGENTS; CELL LINE; CHOLESTENONE 5 ALPHA-REDUCTASE; FATTY ACIDS, NONESTERIFIED; FATTY ALCOHOLS; HUMANS; ISOENZYMES; OXIDOREDUCTASES; PLANT EXTRACTS; SERENOA; SITOSTEROLS; TOCOPHEROLS;

INSECTA; SERENOA REPENS; UNIDENTIFIED BACULOVIRUS;

EID: 0036816014     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(02)00187-5     Document Type: Article

References (33)

1. Krieg M., Nass R., Tunn S. Effect of aging on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrinol. Metab. 77:1993;375-381.
2. Wilson J.D. The pathogenesis of benign prostatic hyperplasia. Am. J. Med. 68:1980;745-756.
3. Isaacs J.T. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle. J. Steroid Biochem. 18:1983;749-757.
4. Span P.N., Schalken J.A., Sweep F.G.J., Smals A.G.H. Identification and partial characterization of two steroid 5α-reductase isoenzymes in the canine prostate. Prostate. 34:1998;222-230.
5. Délos S., Carsol J.-L., Fina F., Raynaud J.-P., Martin P.M. 5α-Reductase and 17β-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate. Int. J. Cancer. 75:1998;840-846.
6. Negri-Cesi P., Poletti A., Colciago A., Magni P., Martini P., Motta M. Presence of 5α-reductase isoenzymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate. 34:1998;283-291.
7. Ielhé C., Radvanyi F., Gil Diez de Medina S., Gérard H., Chopin D., Raynaud J.-P., Martin P.M. Differences in steroid 5α-reductase isoenzymes expression between normal and pathological human prostate tissue. J. Steroid Biochem. Mol. Biol. 68:1999;189-195.
8. Anderson S., Russell D.W. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc. Natl. Acad. Sci. U.S.A. 87:1990;3640-3644.
9. Jenkins E.P., Andersson S., Imperato-McGinley J., Wilson J.D., Russell D.W. Genetic and pharmacological evidence for more than one steroid 5α-reductase. J. Clin. Invest. 89:1992;293-300.
10. Thigpen A.E., Silver R.I., Guileyardo J.M., Casey L.M., McConnell J.D., Russell D.W. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J. Clin. Invest. 92:1993;903-910.
11. Liang T., Liao S. Inhibition of steroid 5α-reductase by specific aliphatic unsaturated fatty acids. Biochem. J. 285:1992;557-562.
12. Lowe C.L., Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology. 53:1999;671-678.
13. Weisser H., Tunn S., Behnke B., Krieg M. Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia. Prostate. 28:1996;300-306.
14. Neuzil E., Cousse H. Le palmier-scie Serenoa repens: aspects botaniques et chimiques. Bull. Soc. Pharm. Bordeaux. 132:1993;121-141.
15. Niederprûm H.J., Schweikert H.U., Zânker K.S. Testosterone 5-reductase inhibition by free fatty acids from Sabal serrulata fruits. Phytomedicine. 1:1994;127-133.
16. Sultan C., Terraza A., Devillier C., Carilla E., Briley M., Loire C., Descomps B. Inhibition of androgen metabolism and binding by a liposterolic extract of Serenoa repens B in human foreskin fibroblasts. J. Steroid Biochem. 20:1984;515-519.
17. Délos S., Carsol J.-L., Ghazarossian E., Raynaud J.-P., Martin P.M. Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. J. Steroid Biochem. Mol. Biol. 55:1995;375-383.
18. ®): a 5α-reductase types I and II inhibitor. New evidence in a co-culture model of BPH. Prostate. 40:1999;232-241.
19. Di Silverio F., Monti S., Sciarra A., Varasano P.A., Martini C., Lanzara S., D'Eramo G., Di Nicola S., Toscano V. Effects of long term treatment with Serenoa repens (Permixon) on the concentration and regional distribution of androgens and epidermal growth factor in BPH. Prostate. 37:1998;77-83.
20. Smith C.M., Ballard S.A., Worman N., Buettner R., Masters J.R.W. 5α-Reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J. Clin. Endocrinol. Metab. 81:1996;1361-1366.
21. Iehlé C., Délos S., Filhol O., Martin P.M. Baculovirus-directed expression of human prostatic steroid 5α-reductase 1 in an active form. J. Steroid Biochem. Mol. Biol. 46:1993;177-182.
22. Luckow V.A., Summers M.D. Trends in the development of baculovirus expression vectors. Biotechnology. 6:1988;47-55.
23. Délos S., Iehlé C., Martin P.M., Raynaud J.-P. Inhibition of the activity of basic 5α-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J. Steroid Biochem. Mol. Biol. 48:1994;347-352.
24. Iehlé C., Délos S., Guirou O., Tate R., Raynaud J.-P., Martin P.M. Human prostatic steroid 5α-reductase isoforms - a comparative study of selective inhibitors. J. Steroid Biochem. Mol. Biol. 54:1995;273-279.
25. M.D. Summers, G.E. Smith, A manual of methods for baculovirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin, 1987, 1555 pp.
26. Le Goff J.M., Martin P.M. Automatic combined system comprising an HPLC apparatus and an on-line radiodetector (Flo-One) for routine analysis of prostatic enzyme activities. Prog. HPLC. 3:1988;79-91.
27. Bonnet P., Reiter E., Bruyninx M., Sente B., Dombrowicz D., De Leval J., Closset J., Hennen G. Benign prostatic hyperplasie and normal prostate aging: differences in types 1 and II 5α-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels. J. Clin. Endocrinol. Metab. 77:1993;1203-1208.
28. Eicheler W., Tuohimaa P., Vilja P., Adermann K., Forssmann W.-G., Aumüller G. Immunocytochemical localization of human 5α-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues. J. Histochem. Cytochem. 42:1994;667-675.
29. Berthault I., Mestayer C., Portois M.-C., Cussenot O., Mowszowicz I. Pharmacological and molecular evidence for the expression of the two steroid 5α-reductase isoenzymes in normal and hyperplastic human prostatic cells in culture. Prostate. 32:1997;155-163.
30. +-4-ene-oxido-reductase) in a stable and active form. J. Steroid Biochem. Mol. Biol. 38:1991;73-77.
31. Kawai C., Ichihara K. Phospholipid requirement of epididymal testosterone 5α-reductase and phospholipid composition of epididymal microsomes. Steroids. 58:1993;472-477.
32. Weisser H., Krieg M. Lipid composition in epithelium and stroma of human benign prostatic hyperplasia. Prostate. 30:1997;41-46.
33. Weisser H., Krieg M. Fatty acid composition in epithelium and stroma of human benign prostatic hyperplasia. Prostate. 36:1998;235-243.